background
hematopoieticcel
transplant
hct
recipi
risk
sever
respiratori
syncyti
viru
rsv
infect
evalu
rsv
fusion
inhibitor
presatovir
random
doubleblind
phase
ii
trial
hct
recipi
rsv
upper
respiratori
tract
infect
method
patient
stratifi
lymphopenia
ribavirin
use
random
stratifi
lymphopenia
ribavirin
use
receiv
oral
presatovir
mg
placebo
day
follow
day
coprimari
efficaci
endpoint
timeweight
averag
chang
nasal
rsv
viral
load
day
proport
patient
develop
lower
respiratori
tract
complic
lrtc
day
result
januari
june
patient
randomli
assign
treatment
presatovir
placebo
presatovir
treatment
compar
placebo
treatment
significantli
affect
prespecifi
timeweight
averag
declin
rsv
viral
load
day
treatment
differ
log
copiesml
confid
interv
ci
log
copiesml
p
progress
lrtc
vs
respect
odd
ratio
ci
p
post
hoc
analysi
among
patient
lymphopenia
presatovir
decreas
lrtc
develop
day
vs
respect
p
compar
placebo
advers
event
similar
patient
receiv
presatovir
placebo
conclus
presatovir
favor
safeti
profil
adult
hct
recipi
rsv
achiev
coprimari
endpoint
exploratori
analys
suggest
antivir
effect
among
patient
lymphopenia
clinic
trial
registr
eudract
adult
recipi
autolog
allogen
hematopoieticcel
transplant
hct
high
risk
respiratori
syncyti
viru
rsv
infect
associ
morbid
mortal
hct
recipi
may
develop
rsv
infect
progress
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
progress
lrti
often
requir
hospit
oxygen
supplement
intens
care
may
requir
rsv
lrti
associ
increas
mortal
rate
rang
survivor
respiratori
viral
infect
hct
may
longterm
airflow
declin
current
effect
vaccin
approv
antivir
agent
rsv
infect
hct
recipi
aerosol
ribavirin
virazol
approv
treatment
rsv
infect
young
children
use
gener
pediatr
practic
efficaci
toler
concern
complex
requir
special
aerosol
deliveri
system
random
placebocontrol
trial
aerosol
ribavirin
attempt
hct
recipi
recruit
subject
year
due
slow
accrual
epidemiolog
studi
singlecent
retrospect
analysi
suggest
ribavirinbas
therapi
efficaci
prevent
rsvassoci
morbid
mortal
highrisk
hct
recipi
howev
result
uncontrol
retrospect
studi
ribavirin
benefit
remain
unconfirm
thu
remain
signific
unmet
medic
need
safe
conveni
effect
treatment
rsv
infect
presatovir
formerli
oral
rsv
fusion
inhibitor
potent
select
antirsv
activ
vitro
termin
halflif
hour
test
human
challeng
studi
healthi
volunt
presatovir
reduc
rsv
viral
load
sever
clinic
diseas
current
studi
evalu
presatovir
safeti
toler
efficaci
among
hct
recipi
rsv
urti
phase
ii
random
doubleblind
placebocontrol
parallel
studi
recruit
allogen
autolog
hct
recipi
posit
local
rsv
test
result
year
age
center
countri
supplementari
appendix
patient
new
worsen
respiratori
symptom
day
diagnos
rsv
infect
upper
respiratori
tract
day
without
new
abnorm
chest
xray
obtain
hour
start
studi
treatment
elig
particip
patient
specifi
document
respiratori
viru
coinfect
within
day
start
studi
treatment
anoth
signific
respiratori
system
infect
exclud
full
elig
criteria
provid
supplementari
method
studi
follow
intern
confer
harmon
requir
principl
declar
helsinki
approv
local
ethic
committe
written
inform
consent
obtain
patient
legal
respons
repres
protocol
amend
data
monitor
committe
activ
describ
supplementari
method
trial
regist
clinicaltrialsgov
eudract
enrol
began
patient
randomli
assign
receiv
presatovir
placebo
stratifi
central
lymphopenia
lymphocyt
count
cellsmm
within
day
screen
prescrib
use
ribavirin
rout
administr
random
studi
treatment
assign
provid
interact
web
respons
system
bracket
global
wayn
pa
usa
patient
studi
staff
studi
sponsor
blind
studi
treatment
alloc
conceal
use
presatovir
placebo
tablet
ident
appear
patient
receiv
presatovir
mg
mg
tablet
placebo
oral
nasogastr
tube
studi
visit
day
hour
follow
studi
day
base
human
pharmacokinet
pharmacodynam
studi
regimen
predict
provid
plasma
concentr
requir
inhibit
replic
test
rsv
isol
patient
detect
rsv
revers
transcript
quantit
polymeras
chain
reaction
rtqpcr
day
could
particip
option
extend
weekli
followup
day
detail
schedul
studi
assess
procedur
provid
supplementari
tabl
plasma
pharmacokinet
method
describ
supplementari
method
virolog
assess
bilater
intranas
swab
obtain
use
midturbin
adult
flock
swab
copan
diagnost
murrieta
ca
studi
visit
sampl
analyz
use
rtqpcr
measur
rsv
viral
load
rsv
f
gene
sequenc
detect
develop
resist
multiplex
assay
identifi
respiratori
viral
coinfect
nasal
sampl
analyz
central
laboratori
methodolog
detail
provid
supplementari
method
chest
xray
comput
tomographi
scan
perform
per
standard
care
patient
suspect
lower
respiratori
tract
complic
lrtc
imag
studi
result
local
microbiolog
test
collect
review
endpoint
adjud
committe
clinic
safeti
assess
includ
vital
sign
bodi
weight
oxygen
satur
puls
oximetri
laboratori
safeti
assess
includ
complet
blood
cell
count
liver
enzym
measur
cardiac
safeti
assess
via
electrocardiogram
troponin
test
per
us
food
drug
administr
cardiac
monitor
requir
day
addit
safeti
assess
includ
evalu
advers
event
ae
document
concomit
medic
coprimari
endpoint
timeweight
averag
chang
nasal
rsv
viral
load
measur
rtqpcr
log
copiesml
day
day
proport
patient
develop
lrtcsdefin
primari
rsv
lrti
secondari
bacteri
lrti
lower
respiratori
tract
infect
due
unusu
pathogen
lrtc
unknown
etiologyfrom
day
day
develop
lrtc
determin
independ
blind
endpoint
adjud
committe
detail
supplementari
method
secondari
efficaci
endpoint
proport
patient
die
develop
respiratori
failur
requir
invas
mechan
ventil
day
day
safeti
assess
ae
vital
sign
electrocardiogram
clinic
laboratori
test
result
assum
timeweight
averag
chang
rsv
viral
load
day
day
log
copiesml
standard
deviat
sd
log
lrtc
event
rate
patient
receiv
placebo
patient
per
treatment
group
plan
provid
power
detect
decreas
first
coprimari
endpoint
power
detect
reduct
second
coprimari
endpoint
patient
receiv
presatovir
rel
placebo
efficaci
popul
includ
patient
receiv
dose
presatovir
quantifi
nasal
rsv
viral
load
day
coprimari
secondari
endpoint
analyz
efficaci
popul
prespecifi
subgroup
defin
random
stratif
factor
lymphopenia
ribavirin
use
day
also
analyz
post
hoc
subgroup
defin
durat
rsv
symptom
hospit
statu
time
hct
graftvshost
diseas
gvhd
statu
day
safeti
popul
includ
patient
receiv
dose
presatovir
first
coprimari
analysi
perform
parametr
analysi
covari
baselin
viral
load
random
stratif
factor
covari
second
coprimari
analysi
secondari
efficaci
analysi
perform
use
cochranmantelhaenszel
test
stratifi
lymphopenia
cellsmm
intent
use
ribavirin
baselin
number
event
small
fisher
exact
method
appli
fallback
approach
employ
control
type
error
rate
across
coprimari
secondari
endpoint
detail
supplementari
method
subgroup
analys
perform
use
correspond
analysi
covari
model
first
coprimari
endpoint
fisher
exact
test
confid
interv
ci
base
clopperpearson
method
second
coprimari
secondari
endpoint
januari
june
patient
screen
elig
patient
exclud
major
n
document
rsv
infect
upper
respiratori
tract
total
patient
randomli
assign
studi
treatment
presatovir
placebo
receiv
dose
studi
drug
receiv
presatovir
receiv
placebo
figur
sponsor
halt
studi
septemb
achiev
plan
enrol
unplan
interim
analysi
databas
lock
unblind
team
indic
result
unlik
differ
enrol
extend
anoth
rsv
season
import
protocol
deviat
describ
supplementari
result
supplementari
tabl
overal
patient
assign
presatovir
placebo
complet
treatment
studi
drug
day
figur
patient
demograph
baselin
clinic
characterist
gener
well
balanc
treatment
group
except
hospit
larger
number
patient
receiv
presatovir
compar
placebo
begin
studi
treatment
vs
respect
tabl
major
treat
patient
underw
allogen
hct
gvhd
baselin
lymphopenia
note
patient
patient
treat
aerosol
oral
ribavirin
baselin
tabl
efficaci
figur
b
show
absolut
rsv
viral
load
chang
baselin
studi
visit
despit
adequ
plasma
concentr
supplementari
result
supplementari
tabl
presatovir
significantli
prespecifi
reduc
timeweight
averag
chang
rsv
viral
load
day
day
compar
placebo
mean
sd
log
copiesml
vs
sd
log
copiesml
respect
treatment
differ
log
copiesml
ci
log
copiesml
p
develop
lrtc
day
shown
figur
compar
placebo
presatovir
significantli
reduc
proport
patient
efficaci
popul
develop
lrtc
day
day
event
treatment
arm
attribut
primari
rsv
lrti
event
presatovir
arm
adjud
secondari
bacteri
infect
sensit
analys
report
supplementari
result
death
respiratori
failur
requir
mechan
ventil
day
occur
patient
receiv
presatovir
patient
receiv
placebo
p
figur
prespecifi
subgroup
analys
presatovir
numer
decreas
proport
patient
develop
lrtc
day
day
rel
placebo
among
patient
baselin
lymphopenia
tabl
supplementari
tabl
proport
patient
receiv
presatovir
develop
lrtc
similar
among
patient
without
baselin
lymphopenia
patient
without
ribavirin
use
baselin
compar
receiv
placebo
supplementari
tabl
overal
ribavirin
use
higher
among
patient
develop
lrtc
versu
patient
hospit
baselin
numer
higher
rate
lrtc
rel
valu
n
presatovir
n
placebo
n
total
c
valu
n
placebo
n
total
hospit
statu
imbalanc
presatovir
placebo
arm
baselin
effect
presatovir
versu
placebo
treatment
timeweight
averag
chang
viral
load
day
day
occurr
death
respiratori
failur
requir
mechan
ventil
day
similar
patient
hospit
hospit
day
supplementari
tabl
howev
treatment
presatovir
rel
placebo
associ
lower
lrtc
event
rate
among
patient
hospit
day
tabl
supplementari
tabl
post
hoc
analys
proport
patient
develop
lrtc
numer
lower
follow
presatovir
treatment
compar
placebo
treatment
among
patient
shorter
median
symptom
durat
day
day
sinc
hct
tabl
supplementari
tabl
post
hoc
multivari
cox
proport
hazard
model
time
lrtc
day
patient
receiv
presatovir
adjust
lymphopenia
ribavirin
use
day
enrol
site
hospit
statu
day
yield
adjust
hazard
ratio
ci
p
compar
receiv
placebo
option
extend
rsv
monitor
serolog
respons
present
supplementari
result
patient
treatmentemerg
substitut
rsv
f
associ
presatovir
resist
numer
smaller
chang
timeweight
averag
rsv
load
wors
clinic
outcom
rel
wildtyp
f
sequenc
substitut
occur
significantli
higher
frequenc
patient
versu
without
lymphopenia
supplementari
result
supplementari
tabl
overal
ae
report
patient
receiv
presatovir
patient
receiv
placebo
patient
receiv
presatovir
patient
receiv
placebo
seriou
advers
event
sae
common
ae
diarrhea
nausea
pyrexia
patient
receiv
presatovir
diarrhea
vomit
nausea
patient
receiv
placebo
tabl
grade
ae
sae
occur
less
frequent
patient
receiv
presatovir
except
pyrexia
sae
patient
gvhd
gastrointestin
tract
sae
grade
pyrexia
grade
pneumonia
patient
supplementari
tabl
imbal
new
electrocardiogram
find
troponin
abnorm
group
overal
patient
die
studi
treat
presatovir
treat
placebo
patient
receiv
presatovir
die
gastrointestin
hemorrhag
pneumonia
patient
receiv
placebo
die
lrti
pneumonia
recurr
acut
myeloid
leukemia
intracrani
hemorrhag
largest
random
doubl
blind
placebocontrol
clinic
trial
date
treatment
allogen
autolog
hct
recipi
rsv
urti
presatovir
treatment
meet
coprimari
endpoint
greater
timeweight
averag
chang
rsv
viral
load
day
reduc
develop
lrtc
day
well
toler
compar
safeti
profil
rel
placebo
post
hoc
analysi
patient
lymphopenia
proport
develop
lrtc
day
lower
follow
treatment
presatovir
compar
placebo
post
hoc
analys
also
indic
trend
toward
treatment
effect
lrtc
result
suggest
lesson
design
futur
clinic
trial
drug
rsv
respiratori
virus
transplant
recipi
immunocompromis
patient
among
healthi
adult
establish
experiment
rsv
infect
presatovir
treatment
compar
placebo
treatment
significantli
reduc
rsv
load
clinic
sever
current
studi
reproduc
find
like
challeng
studi
particip
receiv
presatovir
symptom
onset
wherea
current
studi
patient
treat
median
day
symptom
exploratori
analysi
reveal
trend
toward
reduc
lrtc
rate
follow
presatovir
treatment
versu
placebo
treatment
patient
median
shorter
symptom
durat
tabl
futur
studi
antirsv
drug
particularli
fusion
inhibitor
explor
whether
earlier
therapi
improv
treatment
outcom
transplant
center
treat
rsv
infect
immunocompromis
patient
oral
aerosol
ribavirin
despit
lack
random
clinic
trial
evid
ribavirin
use
rsvinfect
hct
recipi
especi
urti
associ
favor
outcom
retrospect
studi
current
studi
placebotr
patient
receiv
ribavirin
higher
lrtc
progress
rate
compar
vs
respect
patient
develop
lrtc
use
ribavirin
frequent
rel
without
progress
random
control
studi
ribavirin
treatment
observ
requir
confirm
observ
rate
lrtc
lower
expect
use
sampl
size
calcul
day
mortal
low
rel
previou
retrospect
studi
possibl
due
recruit
less
sever
ill
patient
would
typic
undergo
rsv
test
lymphopenia
welldescrib
risk
factor
lrtc
rsvinfect
hct
recipi
observ
current
studi
placebotr
patient
lymphopenia
vs
without
treatment
presatovir
reduc
develop
lrtc
patient
lymphopeniaa
surrog
marker
impair
tcell
humor
immunityposs
robust
immun
respons
mask
treatment
effect
improv
outcom
regardless
treatment
furthermor
lymphopenia
could
influenc
respiratori
immunopatholog
provid
better
evid
presatovir
antivir
efficaci
perhap
import
question
whether
allcaus
lrtc
rate
clinic
relev
endpoint
whether
observ
trend
clinic
meaning
respiratori
failur
mortal
clinic
signific
rate
studi
suggest
sampl
size
requir
would
prohibit
especi
hct
recipi
current
studi
endpoint
lrtc
includ
multipl
etiolog
rsv
urti
may
predispos
patient
secondari
infectionsfor
exampl
disrupt
mucociliari
function
treatment
could
prevent
secondari
lrti
well
primari
lrti
furthermor
lrtc
clinic
signific
event
may
prolong
hospit
necessit
intens
clinic
care
includ
empir
antimicrobi
treatment
potenti
result
death
minor
lrtc
studi
adjud
primari
rsv
lrtislik
due
etiolog
well
lack
lower
respiratori
tract
sampl
confirm
rsvunderscor
potenti
import
nonvir
pulmonari
event
hct
recipi
rsv
infect
determin
caus
lrtc
event
clinic
trial
ideal
requir
invas
procedur
eg
bronchoscopi
lung
biopsi
could
pose
signific
patient
risk
global
mandat
current
clinic
standard
care
thu
radiograph
confirm
corrobor
clinic
data
central
blind
adjud
use
may
best
approach
classifi
lrti
whether
rel
reduct
lrtc
event
clinic
meaning
despit
lack
statist
signific
left
interpret
consist
trend
toward
treatment
effect
exploratori
analys
need
confirm
futur
studi
summari
studi
provid
import
lesson
design
futur
clinic
trial
drug
rsv
respiratori
viru
infect
hct
recipi
although
coprimari
endpoint
achiev
presatovir
treatment
associ
trend
toward
antivir
effect
clinic
benefit
similar
futur
trial
judici
select
suitabl
atrisk
patient
ie
patient
lymphopenia
neutropenia
median
durat
respiratori
symptom
day
efficaci
popul
day
gvhd
receiv
corticosteroid
maxim
potenti
benefit
lrtc
increas
mortal
risk
prompt
diagnos
earli
intervent
rsv
urti
highrisk
patient
effect
antivir
agent
imper
improv
clinic
outcom
